See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus

Oleg Kurtenkov

https://www.etis.ee/CV/Oleg_Kurtenkov/est
27.12.1939
6593932
oleg.kurtenkov@tai.ee

Teenistuskäik

Töökohad ja ametid
01.01.2015–15.05.2017   
Tervise Arengu Instituut, onkoloogia ja immunoloogia osakonna juhataja (0,50)
2003–31.12.2014   
Tervise Arengu Instituut, onkoloogia ja immunoloogia osakonna juhataja (1,00)
01.01.1991–31.12.2003   
Eksperimentaalse ja Kliinilise Meditsiini Instituut (EKMI), eksperimentaalse onkoloogia osakonna juhataja
01.01.1974–31.12.1991   
EKMI, vanemteadur
01.01.1970–31.12.1974   
EKMI, teadur
01.01.1967–31.12.1969   
EKMI, aspirantuur onkoloogia alal
01.01.1965–31.12.1967   
Tallinna Keskhaigla, internatuur kirurgia alal
01.01.1962–31.12.1965   
Tuula oblast, Venemaa, kirurg
 
 
Haridustee
1990–...   
Täiendõpe USA Roswell Park Cancer Institute, Buffalo, New York (aprill-mai 1990)
1956–1962   
Leningradi I Meditsiini Instituut, arstiteaduskond, ravi eriala, arsti kvalifikatsioon
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
1995−...   
New York´i Teaduste Akadeemia liige
1995−...   
Eesti Immunoloogide Seltsi liige
1992−...   
Balti Immunoloogide Seltsi liige
 
 
Loometöö
Ühe leiutise autor:
Kurtenkov Oleg ja Smorodin Jevgeni. " Mao vähi ja healoomuliste haiguste diferentsiaaldiagnostika meetod" Eksperimentaalse ja Kliinilise Meditsiini Instituut. Autoritunnistus nr SU1300678 A1. NSV Liidu Leiutiste ja Avastuste Komitee. 1.12.1986..

Kvalifikatsioon

Teaduskraadid
Oleg Kurtenkov, doktorikraad, 1988, (juh) , Иммунологические аспекты рака желудка: диагностика, мониторинг, прогнозирование. (Maovähi immunoloogilised aspektid. diagnostika, monitooring ja prognoos.), Leningradi N.Petrovi nim. Onkoloogia Instituut.
Oleg Kurtenkov, doktorikraad, 1971, (juh) Kaljo Villako, Макромолекулярные вещества в желудочном соке при раке и предраковых заболеваниях желудка (Maomahla makromolekulaarsed ühendid vähi ja vähieelsete haiguste korral), Tartu Ülikool.
 
 
Teaduspreemiad ja tunnustused
1994, Oleg Kurtenkov, Eesti Vabariigi arstiteaduste aastapreemia laureaat
 
 
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.1. Biomeditsiin; CERCS KLASSIFIKAATOR: B726 Kliiniline bioloogia ; TÄPSUSTUS: Kasvaja immunoloogia: kasvajamarkerid, kasvaja-vastased antikehad ja nende glükosüleeritus; kasvaja immunodiagnostika, monitoring, prognoos ja immuunravi.

Lõppenud projektid

Juhendamisel väitekirjad

Juhendatud väitekirjad

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2020
Kurtenkov, Oleg (2020). Profiling of naturally occurring antibodies to the Thomsen-Friedenreich Antigen in health and cancer: the diversity and clinical potential. BioMed Research International, 9747040. DOI: 10.1155/2020/9747040.
1.1.
2018
Kurtenkov, O.; Bubina, M.; Klaamas, K. (2018). Signatures of anti-Thomsen-Friedenreich antigen antibody diversity in colon cancer patients. Experimental Oncology, 40 (1), 48−58.
1.1.
2015
Kurtenkov, O; Klaamas, K. (2015). Increased avidity of the Sambucus nigra lectin-reactive antibodies to the Thomsen-Friedenreich antigen as a potential biomarker for gastric cancer. Disease Markers, 2015, 0−8.10.1155/2015/761908.
1.1.
2014
Smorodin, E; Sergeyev, B; Kurtenkov, O. (2014). The characterization of IgG antibodies to GalNAc beta - terminated glycans of gastric cancer survivors. Experimental Oncology, 36, 1, 38−43.
1.1.
2014
Kurtenkov, O; Izotova, J; Klaamas, K; Sergeyev, B. (2014). Increased Sialylation of Anti-Thomsen-Friedenreich Antigen (CD176) Antibodies in Patients with Gastric Cancer: A Diagnostic and Prognostic Potential. BioMed Research International, 2014, 0−11.10.1155/2014/830847.
3.1.
2014
Sergejev, K.; Klaamas, K.; Land, R.; Kurtenkov, O. (2014). Electrochemical Impedance Spectroscopy Analysis of Immunoglobulin G in Patients with Gastric Cancer. Proceedings of the 14th Biennial Baltic Electronics Conference: 2014 14th Biennial Baltic Electronics Conference, Tallinn, 2014. IEEE, 189−192.
1.1.
2013
Smorodin, E.; Kurtenkov, O.; Sergeyev, B. (2013). The level of anti- (GalNAc beta) and anti.Para-Forssman disaccharide IgG antibodies in patients with gastrointestinal cancer: relation to survival. Experimental Oncology, 35 (2), 89−92.
1.1.
2013
Smorodin, E.; Sergeyev, B.; Klaamas, K.; Chuzmarov, V.; Kurtenkov, O. (2013). The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients. International Journal of Medical Sciences, 10, 12, 1674−1682.10.7150/ijms.6841.
1.1.
2012
Kodar, Kristel; Stadlmann, Johannes; Klaamas, Kersti; Sergeyev, Boris; Kurtenkov, Oleg. (2012). Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconjugate Journal, 29, 57−66.10.1007/s10719-011-9364-z.
1.1.
2011
Smorodin, Eugeniy; Kurtenkov, Oleg; Sergeyev, Boris; Branovets, Jelena; Izotova, Jelena; Formanovsky, Andrey (2011). Specificity of serum anti-A(di) IgG antibodies from patients with gastrointestinal cancer. Journal of Immunoassay and Immunochemistry, 32, 170−190.
1.2.
2011
Smorodin, E; Kurtenkov, O; Sergeyev, B; Klaamas, K; Izotova, J. (2011). The Characterization of Cross-reactive Antibodies to Thomsen-Friedenreich alpha/beta and Related Glycan-conjugates with Polyacrylamide Carriers in Patients with Gastrointestinal Cancer. Journal of Clinical & Cellular Immunology, 1−8. DOI: 10.4172/2155-9899.S5-001.
1.1.
2010
Pandey, J; Namboodiri, A; Kurtenkov, O; Nietert, P (2010). Genetic regulation of antibody responses to human epidermal growth factor receptor 2 in breast cancer. Human Immunology, 71 (11), 1124−1127. DOI: 10.1016/j.humimm.2010.08.009.
5.2.
2010
Smorodin, E; Kurtenkov, O; Sergeyev, B (2010). The Characterizarion of IgG Antibodies to A and Blood Group Related Antigens in Patients With Cancer: Adi, Adi/Bdi/Btri and Adi/Atri/FSdi/Core5 Reactive Antibodies. Scandinavian Journal of Immunology, 71/6: 39th meeting of Scandinavian Society for Immunology jointly with the Baltic Immunological Society, June 2-5, 2010, Tallinn, Estonia. Blackwell Publishing Ltd, 503.
5.2.
2010
Kurtenkov, O; Kodar, K; Klaamas, K; Izotova, J (2010). Aberrant glycosylation of the Thomsen-Friedenreich Glycotope-Specific IgG is Associated With the Survival of Cancer patients. Scandinavian Journal of Immunology, 71/6: 39th meeting of Scandinavian Society for Immunology jointly with the Baltic Immunological Society, June 2-5, 2010, Tallinn, Estonia. Blackwell Publishing Ltd, 501.
5.2.
2010
Kodar, K; Stadlmann, J; Kurtenkov, O; Klaamas, K (2010). Human IgG Fc glycan profiling in patients with gastric cancer by LC-ESI-MS. Glycomarkers For Disease: The Euro Glycosciences Forum, September 12th-16th 2010, Wierzba, Poland. , 42.
1.1.
2009
Kodar, Kristel; Kurtenkov, Oleg; Klaamas, Kersti (2009). The Thomsen-Friedenreich Antigen and αGal- specific Human IgG Glycoforms: Concanavalin A Reactivity and Relation to Survival of Cancer Patients. Immunological Investigations, 38, 8, 704−717.
1.1.
2009
Pandey, Janardan; Nietert, Paul; Klaamas, Kersti; Kurtenkov, Oleg (2009). A genetic variant of immunoglobulin γ2 is strongly associated with immunity to mucin 1 in patients with breast cancer. Cancer Immunology Immunotherapy, 58, 2025−2029. DOI: 10.1007/s00262-009-0709-4.
26.01.2022

Oleg Kurtenkov

https://www.etis.ee/CV/Oleg_Kurtenkov/eng
27.12.1939
6593932
oleg.kurtenkov@tai.ee

Career

Institutions and positions
01.01.2015–15.05.2017   
National Institute for Health Development, head, department of oncology and immunology (0,50)
2003–31.12.2014   
National Institute for Health Development, head, department of oncology and immunology (1,00)
01.01.1991–31.12.2003   
IECM, head of the Department of Experimental Oncology.
01.01.1974–31.12.1991   
­IECM, senior researcher
01.01.1970–31.12.1974   
­IECM, researcher
01.01.1967–31.12.1969   
postgraduate student. Department of Oncology, Institute of Experimental and Clinical Medicine (IECM), Tallinn
01.01.1965–31.12.1967   
intern in surgery at Central Hospital, Tallinn
01.01.1962–31.12.1965   
surgeon, Tula district, Russia
 
 
Education
1990–...   
Advanced course at Roswell Park Cancer Institute, Buffalo, New York, USA
1956–1962   
Leningrad Ist Medical Institute, physician
 
 
R&D related managerial and administrative work
1995−...   
New York Academy of Sciences, member
1995−...   
Baltic Immunological Society, member
1992−...   
Estonian Immunological Society, member
 
 
Creative work
Patent
Kurtenkov Oleg and Smorodin Jevgeni. "Gastric cancer diagnostic method" SU 1300678 A1, 1.12.1986.

Qualifications

Academic degrees
Oleg Kurtenkov, Doctor's Degree, 1988, (sup) , Иммунологические аспекты рака желудка: диагностика, мониторинг, прогнозирование. (Immunological aspects of gastric cancer: diagnostics, monitoring and prognostics.), Petrov Research Institute of Oncology, Leningrad, Russia.
Oleg Kurtenkov, Doctor's Degree, 1971, (sup) Kaljo Villako, Макромолекулярные вещества в желудочном соке при раке и предраковых заболеваниях желудка (Macromolecular substances in the gastric juice in cancer and precancerous diseases of the stomach), University of Tartu.
 
 
Honours & awards
1994, Oleg Kurtenkov, Inventor in field of oncology.Honoured with scientific prize of Estonia
 
 
Fields of research
ETIS CLASSIFICATION: 3. Health; 3.1. Biomedicine; CERCS CLASSIFICATION: B726 Clinical biology ; SPECIFICATION: Tumor immunology: cancer biomarkers, tumor-related antibodies and antibody glycosylation, cancer immunodiagnostics, monitoring, prognostics and therapy.
 
 

Completed projects

Dissertations under supervision

Supervised dissertations

Publications

Category
Year
Publication
 
1.1.
2020
Kurtenkov, Oleg (2020). Profiling of naturally occurring antibodies to the Thomsen-Friedenreich Antigen in health and cancer: the diversity and clinical potential. BioMed Research International, 9747040. DOI: 10.1155/2020/9747040.
1.1.
2018
Kurtenkov, O.; Bubina, M.; Klaamas, K. (2018). Signatures of anti-Thomsen-Friedenreich antigen antibody diversity in colon cancer patients. Experimental Oncology, 40 (1), 48−58.
1.1.
2015
Kurtenkov, O; Klaamas, K. (2015). Increased avidity of the Sambucus nigra lectin-reactive antibodies to the Thomsen-Friedenreich antigen as a potential biomarker for gastric cancer. Disease Markers, 2015, 0−8.10.1155/2015/761908.
1.1.
2014
Smorodin, E; Sergeyev, B; Kurtenkov, O. (2014). The characterization of IgG antibodies to GalNAc beta - terminated glycans of gastric cancer survivors. Experimental Oncology, 36, 1, 38−43.
1.1.
2014
Kurtenkov, O; Izotova, J; Klaamas, K; Sergeyev, B. (2014). Increased Sialylation of Anti-Thomsen-Friedenreich Antigen (CD176) Antibodies in Patients with Gastric Cancer: A Diagnostic and Prognostic Potential. BioMed Research International, 2014, 0−11.10.1155/2014/830847.
3.1.
2014
Sergejev, K.; Klaamas, K.; Land, R.; Kurtenkov, O. (2014). Electrochemical Impedance Spectroscopy Analysis of Immunoglobulin G in Patients with Gastric Cancer. Proceedings of the 14th Biennial Baltic Electronics Conference: 2014 14th Biennial Baltic Electronics Conference, Tallinn, 2014. IEEE, 189−192.
1.1.
2013
Smorodin, E.; Kurtenkov, O.; Sergeyev, B. (2013). The level of anti- (GalNAc beta) and anti.Para-Forssman disaccharide IgG antibodies in patients with gastrointestinal cancer: relation to survival. Experimental Oncology, 35 (2), 89−92.
1.1.
2013
Smorodin, E.; Sergeyev, B.; Klaamas, K.; Chuzmarov, V.; Kurtenkov, O. (2013). The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients. International Journal of Medical Sciences, 10, 12, 1674−1682.10.7150/ijms.6841.
1.1.
2012
Kodar, Kristel; Stadlmann, Johannes; Klaamas, Kersti; Sergeyev, Boris; Kurtenkov, Oleg. (2012). Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconjugate Journal, 29, 57−66.10.1007/s10719-011-9364-z.
1.1.
2011
Smorodin, Eugeniy; Kurtenkov, Oleg; Sergeyev, Boris; Branovets, Jelena; Izotova, Jelena; Formanovsky, Andrey (2011). Specificity of serum anti-A(di) IgG antibodies from patients with gastrointestinal cancer. Journal of Immunoassay and Immunochemistry, 32, 170−190.
1.2.
2011
Smorodin, E; Kurtenkov, O; Sergeyev, B; Klaamas, K; Izotova, J. (2011). The Characterization of Cross-reactive Antibodies to Thomsen-Friedenreich alpha/beta and Related Glycan-conjugates with Polyacrylamide Carriers in Patients with Gastrointestinal Cancer. Journal of Clinical & Cellular Immunology, 1−8. DOI: 10.4172/2155-9899.S5-001.
1.1.
2010
Pandey, J; Namboodiri, A; Kurtenkov, O; Nietert, P (2010). Genetic regulation of antibody responses to human epidermal growth factor receptor 2 in breast cancer. Human Immunology, 71 (11), 1124−1127. DOI: 10.1016/j.humimm.2010.08.009.
5.2.
2010
Smorodin, E; Kurtenkov, O; Sergeyev, B (2010). The Characterizarion of IgG Antibodies to A and Blood Group Related Antigens in Patients With Cancer: Adi, Adi/Bdi/Btri and Adi/Atri/FSdi/Core5 Reactive Antibodies. Scandinavian Journal of Immunology, 71/6: 39th meeting of Scandinavian Society for Immunology jointly with the Baltic Immunological Society, June 2-5, 2010, Tallinn, Estonia. Blackwell Publishing Ltd, 503.
5.2.
2010
Kurtenkov, O; Kodar, K; Klaamas, K; Izotova, J (2010). Aberrant glycosylation of the Thomsen-Friedenreich Glycotope-Specific IgG is Associated With the Survival of Cancer patients. Scandinavian Journal of Immunology, 71/6: 39th meeting of Scandinavian Society for Immunology jointly with the Baltic Immunological Society, June 2-5, 2010, Tallinn, Estonia. Blackwell Publishing Ltd, 501.
5.2.
2010
Kodar, K; Stadlmann, J; Kurtenkov, O; Klaamas, K (2010). Human IgG Fc glycan profiling in patients with gastric cancer by LC-ESI-MS. Glycomarkers For Disease: The Euro Glycosciences Forum, September 12th-16th 2010, Wierzba, Poland. , 42.
1.1.
2009
Kodar, Kristel; Kurtenkov, Oleg; Klaamas, Kersti (2009). The Thomsen-Friedenreich Antigen and αGal- specific Human IgG Glycoforms: Concanavalin A Reactivity and Relation to Survival of Cancer Patients. Immunological Investigations, 38, 8, 704−717.
1.1.
2009
Pandey, Janardan; Nietert, Paul; Klaamas, Kersti; Kurtenkov, Oleg (2009). A genetic variant of immunoglobulin γ2 is strongly associated with immunity to mucin 1 in patients with breast cancer. Cancer Immunology Immunotherapy, 58, 2025−2029. DOI: 10.1007/s00262-009-0709-4.
26.01.2022

Otsi projekti

  • {{item.Name}}
Asutus on projekti finantseerija   Asutus on projekti teostaja  
  • {{searchListItem.Name}}
Kõik   Tavaprojektid   Ülemprojektid   Alamprojektid  
Uus Frascati (2015)
Uus ja vana Frascati (otsing uue järgi väljastab ka seotud vanad)
Kõik
Käimasolevad
Lõppenud
Algus
Hajus
Täpne
Uus otsing (Beetaversioon) Lihtotsing Tühjenda
  • Leitud 6 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
ETFETF8399Autoantikehad kasvajaseoselise Thomsen-Friedenreich (TF) disahhariidi vastu: subpopulatsioonid, TF glükotoobi loomulikud kandjad ja seos tuumorprogressiooniga 01.01.201031.12.2013Oleg KurtenkovTervise Arengu Instituut64 069,95 EUR
SFSF0192109s02Helicobacter pylori infektsioon ja gastroduodenaalne patoloogia: peremehest ja mikroobist sõltuvate tegurite roll infektsiooni kliinilises väljundis (krooniline gastriit, peptiline haavand, maovähk).01.01.200231.12.2006Oleg KurtenkovTervise Arengu Instituut277 057,00 EUR
ETFETF6726Immuunvastus sünteetilistele kasvajaseoselistele süsivesikantigeenidele ja loomulikele sihtmärkidele vähihaigetel: IgG antikehade spetsiifilisus ja kliiniline tähendus01.01.200631.12.2009Oleg KurtenkovTervise Arengu Instituut49 344,92 EUR
ETFETF7317Kasvajaseoseliste antigeenide vastaste autoantikehade glükosüleeritus vähi ja vähieelsete seisundite korral.01.01.200831.12.2011Kersti KlaamasTervise Arengu Instituut66 953,95 EUR
PUT; PUT_OPPUT371Kasvajaseoseliste glükaanide vastaste antikehade aberrantne glükosüleeritus vähi diagnostikas ja haiguse kulu prognoosimisel01.01.201431.12.2017Kersti KlaamasTervise Arengu Instituut163 200,00 EUR
SFSF0140145Bs08Tuumorprogressiooni immunoloogia: kasvajaseoseliste antigeenide vastase immuunvastuse profüleerimine vähi diagnostikas, monitooringus ja prognoosimises01.01.200831.12.2013Oleg KurtenkovTervise Arengu Instituut598 694,01 EUR